Cell Genesys Inc

Cell Genesys — Merger or Acquisition (August 2009)

19 slides from Cell Genesys's merger presentation, Aug 7, 2009

  1. Slide 1: Elestrin

    Elestrin = cate A008 Elestri Santex , Pharmaceuticals

  2. Slide 2: BioSante Investment Highlights

    BioSante Investment Highlights Products FDA approved product (Elestrin™) Potential “blockbuster” product (LibiGel®) Deep late stage product portfolio People Experienced management team Product development and FDA expertise Licensing and M & A expertise Finances Cell Genesys merger (announced June 30

  3. Slide 3: BioSante Mission and Lead Product Portfolio

    BioSante Mission: Develop and market products to treat unmet medical needs Lead product portfolio Calcium phosphate technology (CaP) Aesthetic medicine, e.g., facial line filler H1N1 vaccine adjuvant/drug delivery FDA submission < 12 months Male hypogonadism Bio-T-Gel™ Phase II Contraception The Pil

  4. Slide 4: Elestrin (estradiol gel)

    Indication: Once daily transdermal gel for treatment of moderate-to-severe vasomotor symptoms Symptoms: Hot flashes Market Size: Market Data [U.S. only]: Estrogen therapy (ET) market: ~$1.4 billion Transdermal segment: about $260 million Estimated to reach $400 million in 2010/11 20 million menopaus

  5. Slide 5: LibiGel (testosterone gel for women)

    Indication: Female Sexual Dysfunction (FSD) Symptoms: Lack of sexual desire, arousal or pleasure Market Size: Estimated U. S. market more than $2 billion LibiGel could be first FSD Rx product to market in U.S targeting menopausal women Status: Two SPAs Received in 2008! Two Phase III efficacy studie

  6. Slide 6: LibiGel SPA

    LibiGel® (testosterone gel for women) SPA The SPA affirms that female sexual dysfunction (FSD) is a diagnosable condition with measurable endpoints for study and therapy deserving of therapeutic options for treatment The SPA process and agreement affirms FDA agreement that the LibiGel Phase III clin

  7. Slide 7: Comparative Results

    ~ 30% ~ 30% rare Application site reactions 1.56 v. 0.73* 2.13 v. 0.98* 5.0 v. 1.6* # increase active v. placebo 51%* 74%* 238%* % increase in sexual events from baseline 6 month Phase III 300 mcg/day N=533 SM 6 month Phase III 300 mcg/day N=562 SM 3 month Phase II 300 mcg/day N=46 SM Study Design B

  8. Slide 8: Mean Change From Baseline: LibiGel vs. Intrinsa

    Mean Change From Baseline p<0.05 3.4 * p<0.0001 versus baseline 5.0 * 1.6 3.9 2.6 Estrogen-treated SM women Month 1 Month 2 Month 3 Month 6 2.1 1.0 1.1 p<0.0003 LibiGel® vs. Intrinsa® Mean Change From Baseline in 4-Week Satisfying Sexual Event Rate 0 1 2 3 4 5 Placebo LibiGel 300 mcg/d Intrinsa Plac

  9. Slide 9: LibiGel Potential Market

    LibiGel® (testosterone gel for women) Potential Market Market potential for FSD is more than $2.0 billion 43% of women (18-59) experience some degree of FSD (JAMA) 31% experience low sexual desire specifically 31% of men experience sexual dysfunction 43% of women (57-85) experience low desire (NEJM)

  10. Slide 10: Physician Need for FDA-Approved HSDD Therapy

    7580 HSDD Defined Health - Pg. 11 Greater than 80% of physicians surveyed indicate that there is a need (or great need) for an FDA-approved therapy for HSDD. Executive Summary Physicians report a high level of need for an effective, safe and FDA approved product for HSDD. N= 51 Level of Need for FDA

  11. Slide 11: HSDD Market Assumptions

    7580 HSDD Defined Health - Pg. 12 Assumptions: US launch early 2011. Diagnosis rate moves from 30% to 50% with a drug labeled for HSDD and education for physicians and patients. 40% increase in current treatment rate. 30% of patients discontinue treatment due to androgenic side effects (15%) or lack

  12. Slide 12: Limited Competition in US HSDD Market

    7580 HSDD Defined Health - Pg. 13 ADIS, Companies’ websites Phase II Phase III Efficacy Flibanserin (HSDD)-Boehringer Ingelheim Luramist (HSDD)-VIVUS Testosterone Products Non-Testosterone Products Pre-Menopausal Women Menopausal Women There is limited competition in the US HSDD market as only LibiG

  13. Slide 13: BioSante's Product Portfolio

    CAP Look™ LibiGel® (testosterone gel) Female sexual dysfunction (FSD) The Pill Plus™ (birth control with androgen) Male Hypogonadism Bio-T-Gel™ (testosterone gel) Contraception Elestrin™ (estradiol gel) Early Human Clinical Late Human Clinical FDA approval / Licensees Menopausal symptoms Line-filler

  14. Slide 14: BioSante Pharmaceuticals, Inc. Corporate Summary

    BioSante Pharmaceuticals, Inc. Corporate Summary

  15. Slide 15: Trading Data

    NASDAQ BPAX Common stock outstanding 27.0 million Warrants 2.7 million ($2.50-$8.00) Employee options 2.7 million (average exercise price of $2.93) Fully diluted shares 32.4 million Trading Data

  16. Slide 16: Financial Highlights

    Cash at 6/30/09 Approximately $6.0 million Burn rate Approximately $1.2 million/month Financial Highlights

  17. Slide 17: After Effect of Merger with Cell Genesys

    After Effect of Merger with Cell Genesys Q3/Q4 NASDAQ BPAX Common stock outstanding 44.7 million Warrants 3.1 million Options 2.9 million Fully diluted shares 50.7 million Cash post-closing Approx. $25 million

  18. Slide 18: Achieved / Expected Milestones

    Achieved / Expected Milestones Close merger with Cell Genesys Late Q3/Q4 2009 Elestrin™ FDA approved and marketed Current LibiGel® Two clinical SPAs Received 2008 Three Phase III studies on-going Current Submit NDA H1 2011 Launch LibiGel Q4 2011 The Pill Plus™ Initiated Phase II clinical trials- ora

  19. Slide 19: Elestrin

    Elestrin = cate A008 Elestri Santex , Pharmaceuticals

Cell Genesys — Merger or Acquisition (August 2009) on 6ix